Track Categories
The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.
- TRACK A – Basic Science
- TRACK B – Clinical Science
- TRACK C – Prevention Science
- TRACK D – Implementation Science
HIV Evolution and Phylodynamics (Intra- and Inter-Host)
| A1 |
Viral origins, evolution and diversity |
| A2 |
Viral fitness and resistance |
Virology
| A3 |
Entry (attachment, receptors and co-receptors, penetration and tropism) |
| A4 |
Viral replicative cycle (reverse transcription, integration, viral assembly and maturation) |
| A5 |
Transcriptional and gene expression regulation (including regulatory genes) |
Immune Responses (Innate and Adaptive)
| A6 |
Innate immunity |
| A7 |
Humoural immunity |
| A8 |
Cellular immunity |
| A9 |
Mucosal immunity |
| A10 |
Virus escape from adaptive immunity |
Pathogenesis (Immune Function and Dysfunction)
| A11 |
Systemic immune activation and inflammation |
| A12 |
T cell depletion and reconstitution, and immune ageing |
| A13 |
Microbiomes and microbial translocation |
| A14 |
Latency and viral reservoirs |
| A15 |
Correlates of HIV susceptibility and disease progression (biomarkers and genetics) |
| A16 |
HIV co-morbidities |
| A17 |
Systems biology approaches to HIV infection |
Natural Protection against HIV/AIDS
| A18 |
HIV controllers (including post-treatment controllers) and long term non-progressors |
| A19 |
Highly exposed seronegative individuals (HESN) |
| A20 |
Correlates of immune protection |
Transmission and Early Infection
| A21 |
Mucosal transmission |
| A22 |
Vertical transmission |
| A23 |
Blood borne transmission |
| A24 |
Founder viruses/transmission bottleneck |
| A25 |
Acute and early infection |
Novel Treatment, Prevention and Cure Strategies
| A26 |
Preclinical drug development, including prophylactic drug and microbicide development |
| A27 |
Nucleic acid-based HIV therapies |
| A28 |
Targeting HIV persistence during ART (cure strategies) |
| A29 |
Immunotherapy |
Vaccine Development
| A30 |
Cell-based preventative vaccines |
| A31 |
Adjuvants |
| A32 |
Novel vectors and strategies |
| A33 |
Therapeutic vaccines |
Super- and Co-Infections (Including Opportunistic Infections)
| A34 |
HIV-1 super-infection/inter/intra subtype co-infection |
| A35 |
HIV-2 |
| A36 |
Viral hepatitis |
| A37 |
Mycobacteria and tuberculosis |
| A38 |
Other pathogens |
Diagnostic Tools for Immunological and Virological Monitoring of HIV Infection
| A39 |
Novel assays of immune responses |
| A40 |
Novel approaches to assess viral load and ARV resistance/tropism |
Animal Models (Excluding Latency/Reservoirs)
| A41 |
Viral determinants of SIV pathogenesis |
| A42 |
Animal models of transmission, disease progression and spontaneous control |
| A43 |
Novel animal/virus models for vaccine, cure research and inhibitor development |
Course of HIV Disease
| B1 |
Disease progression |
| B2 |
Acute and early infection (including treatment) |
| B3 |
Long-term non-progressors and elite controllers |
| B4 |
HIV-2 |
| B5 |
Gender differences in HIV |
Diagnostic and Monitoring Tools
| B6 |
HIV testing |
| B7 |
CD4 measurement (including point of care diagnostics) |
| B8 |
Long-term non-progressors and elite controllers |
| B9 |
Viral load measurement (including point of care diagnostics) |
| B10 |
Measuring ART adherence (drug levels, dried blood spots, hair sampling) |
| B11 |
Drug resistance testing |
| B12 |
Diagnostics of co-infections and comorbidities |
Co-Infections (Including Opportunistic Infections)
| B13 |
Opportunistic infections (excluding TB) |
| B14 |
Tuberculosis and other mycobacteria |
| B15 |
Other bacterial, viral and parasitic infections |
| B16 |
Viral hepatitis |
| B17 |
Human papillomavirus |
| B18 |
Syphilis and other STI’s |
Comorbidities and Complications (Including those Related to ART)
| B19 |
Neurologic disorders |
| B20 |
Depression and other psychiatric manifestations |
| B20 |
Depression and other psychiatric manifestations |
| B21 |
AIDS and non-AIDS malignancies |
| B22 |
Lipodystrophy and hyperlipidaemia |
| B23 |
Cardiovascular disease |
| B24 |
Bone disease |
| B25 |
Renal disease |
| B26 |
Metabolic, lipid and endocrine complications, obesity |
| B27 |
Hepatic complications (including NASH) |
| B28 |
Ageing with HIV (including polypharmacy and frailty) |
| B29 |
Immune reconstitution disorders / immune reconstitution inflammatory syndrome (IRIS) |
| B30 |
Other ART complications and adverse reactions |
| B31 |
Biomarkers for the prediction of morbidity and mortality |
| B32 |
Scaling up NCD screening and treatment (clinical aspects) |
| B33 |
Strategies for promoting long-term health |
Antiretroviral Therapies in Adults (Clinical Trials and Observational Cohort Studies)
| B34 |
ART in first- and second-line therapies |
| B35 |
ART in highly treatment-experienced persons |
| B36 |
ART in highly treatment-experienced persons |
| B35 |
Management of late presenters |
| B37 |
Regimen simplification and switch studies |
| B38 |
Pharmacology / pharmacokinetics / pharmacogenomics / role of therapeutic drug monitoring |
| B39 |
Drug interactions |
| B40 |
Antiretroviral drug resistance |
| B41 |
Long-acting agents |
| B42 |
ARVs and HIV reservoirs/immunity relevant to HIV remission and cure |
| B43 |
Ethical issues in clinical trials and treatment strategies |
Other Strategies and Therapies (non-ART)
| B44 |
Therapeutic vaccine trials |
| B45 |
Other immune-based therapy trials |
| B46 |
Complementary and traditional medicines |
| B47 |
Cure interventions (including those aimed at reservoir depletion) |
| B48 |
Novel therapeutic approaches (including gene therapy) |
| B49 |
Pain and palliative medicine |
| B50 |
Nutrition |
Clinical Issues Specific to Women
| B51 |
Clinical management issues and pharmacokinetics during and after pregnancy |
| B52 |
Safe conception for serodiscordant couples |
| B53 |
Menopause and HIV |
| B54 |
Contraception and HIV |
| B55 |
Gender specific issues of ART efficacy, adverse reactions and complications |
Clinical Issues Specific to Paediatric and Adolescent HIV
| B56 |
Diagnosis of HIV disease in paediatric populations |
| B57 |
Engagement and linkage to care in paediatric and adolescent HIV |
| B58 |
Pharmacokinetics / pharmacodynamics / pharmacogenomics in paediatric populations |
| B59 |
Therapeutic drug monitoring in paediatric population |
| B60 |
Drug formulations for infants and children |
| B61 |
Clinical trials in children and adolescents |
| B62 |
Adherence in paediatric and adolescent populations |
| B63 |
HIV complications and comorbidities in children and adolescents |
| B64 |
Opportunistic infections in paediatric and adolescent populations |
| B65 |
HIV-exposed uninfected children |
| B66 |
ARV management strategies in paediatric and adolescent populations |
| B67 |
Behavioural health outcomes in children and adolescents |
| B68 |
Mental health and neuro-cognition in paediatric and adolescent populations |
| B69 |
HIV-associated co-infections and malignancies in paediatric and adolescent populations |
| B70 |
Transition of adolescents into adult care |
Clinical Issues Specific to Key Populations
| B71 |
Clinical issues in men who have sex with men |
| B72 |
Clinical issues in people who use drugs |
| B73 |
Clinical issues in sex workers |
| B74 |
Clinical issues in transgender and non-binary populations (including access to gender affirming care) |
| B75 |
Clinical issues in other key populations |
Epidemiology of HIV
| C1 |
Natural history, progression and survival |
| C2 |
Measurement and modelling of the HIV epidemics |
| C3 |
Risk factors for acquisition, infectivity, progression and transmission of HIV |
| C4 |
Network studies of risk behaviours and their implications for prevention |
| C5 |
Epidemiology of HIV in key populations (MSM, transgender, migrants, serodiscordant couples) |
| C6 |
Epidemiology of opportunistic infections and co-infections |
| C7 |
Epidemiology of serious non-AIDS events |
| C8 |
Epidemiology of AIDS defining and non-AIDS defining cancers and other comorbidities |
| C9 |
Molecular epidemiology |
| C10 |
Determination of HIV incidence |
| C11 |
Diagnosis of HIV infection (detection of acute and recent HIV infection, including self-testing) |
| C12 |
Surveillance of HIV and HIV drug resistance |
| C13 |
Surveillance systems and methods, including geographical information systems |
| C14 |
Population-based surveys with HIV testing and viral load in epidemiology studies |
| C15 |
Measurement of behaviours and adherence, including biomedical measures (including biomedical devices and bioassays) |
| C16 |
Measurement and modelling of the impact of prevention and treatment interventions |
Approaches and Tools for HIV Prevention
| C17 |
STI control to prevent HIV transmission |
| C18 |
Male and female condoms and other physical barriers |
| C19 |
Male circumcision |
| C20 |
PEP, PrEP (long-acting and oral) and microbicides |
| C21 |
Treatment as prevention |
| C22 |
Vaccines (both passive and active) |
| C23 |
Adherence to HIV prevention strategies |
| C24 |
Strategies for identifying key populations |
| C25 |
Use of the internet, social media, mobile phones and other e-devices for prevention |
| C26 |
Integration of HIV prevention services into health and other platforms |
| C27 |
Combination prevention approaches |
| C28 |
Participatory practice and community involvement in prevention research |
| C29 |
Study designs in prevention research |
| C30 |
Ethical and human rights issues in epidemiological, prevention and other research |
| C31 |
Behavioural interventions to prevent HIV transmission |
Prevention of Mother to Child Transmission
| C32 |
Reducing pre-partum and intra-partum transmission to infants |
| C33 |
Reducing post-partum transmission in infants |
| C34 |
Strategies to increase HIV testing in pregnant women and mothers and their partners |
| C35 |
PMTCT services for marginalized populations |
| C36 |
Integration of family planning and HIV services, including coverage and quality of PMTCT programmes) |
| C37 |
Promoting health and reducing maternal mortality in HIV-positive women |
Population-Specific Interventions and HIV Prevention Strategies
| C38 |
Prevention of vertical transmission (including in key and other vulnerable populations) |
| C39 |
Prevention for HIV serodiscordant couples |
| C40 |
Prevention for populations with multiple co-occurring epidemics |
| C41 |
Prevention during acute and recent infection |
| C42 |
Prevention among HIV-infected individuals |
| C43 |
Prevention in health care and other institutional settings |
| C44 |
Prevention addressing gender inequalities |
| C45 |
Prevention of TB among people living with HIV |
| C46 |
Prevention of HIV infection in IVDU |
Feasibility and Impact of Structural Interventions
| C47 |
Assessing impact/cost-effectiveness of structural interventions and social protection |
| C48 |
Gender sensitization, empowerment and violence reduction |
| C49 |
Collectivization, mobilization, stigma reduction programmes |
| C50 |
Policy-level HIV interventions including legal-policy reform |
Infrastructure and Delivery Models for the Scale Up of HIV Services
| D1 |
Methodological challenges to scale up and optimization of services |
| D2 |
Impact evaluation of different models of service delivery |
| D3 |
Provider and facility determinants of outcomes |
| D4 |
Methods to improve provider quality, supply and tailoring of services |
| D5 |
Healthcare workers and volunteers: training, mentoring, retaining, task shifting, safety |
| D6 |
Demand generation for HIV services |
| D7 |
Models of public-private partnerships |
Strategies to Increase Uptake of and Retention in HIV Services
| D8 |
Operational challenges in implementing HIV services |
| D9 |
Socio-economic challenges in implementing HIV services |
| D10 |
Adherence to HIV treatment |
| D11 |
Uptake of HIV services |
| D12 |
Retention in HIV services |
| D13 |
Linkage between HIV services |
| D14 |
Indicators of quality of care |
| D15 |
Differentiated models of care |
| D16 |
Use of financial incentives/behavioural economics |
| D17 |
Combination interventions that span prevention / screening / treatment |
Integration of HIV Services with Other Programmes
| D18 |
Integration of HIV services with other health programmes |
| D19 |
Integration of HIV and HCV services |
| D20 |
Integration of HIV services with other development programmes |
| D21 |
Integration of prevention interventions with care/treatment |
Diagnostics
| D22 |
Scale up of paediatric diagnosis |
| D23 |
Scale up of point-of-care technologies |
| D24 |
Scale up of viral load monitoring |
| D25 |
Optimal split between laboratory-based and point-of-care devices |
Sustainable Financing
| D26 |
National and international financing initiatives |
| D27 |
Transitional financing |
| D28 |
Impact of donor agencies' policies |
| D29 |
Impact of financial crises |
| D30 |
Leveraging HIV funding to strengthen health systems beyond HIV programmes |
| D31 |
Building country ownership in HIV programming |
Health Systems Strengthening
| D32 |
Changes in policy and practice |
| D33 |
Capacity building initiatives |
| D34 |
Translation, incorporation and use of key IR findings into programmes and practice |
Monitoring and Evaluation
| D35 |
Monitoring and evaluation of prevention |
| D36 |
Monitoring and evaluation of testing |
| D37 |
Monitoring and evaluation of treatment and care |
| D38 |
Monitoring and evaluation of HIV cascade |
| D39 |
Monitoring and evaluation of health systems |